SNSW(SH:688117)2022-04-25 16:00Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion for the fiscal year 2021, representing a growth of 25% compared to the previous year[18]. - The company reported a net profit of RMB 300 million, which is a 30% increase compared to the previous fiscal year[18]. - The company achieved operating revenue of CNY 386.53 million in 2021, representing a year-on-year growth of 2.05%[26]. - The net profit attributable to shareholders of the listed company was CNY 61.25 million, an increase of 2.09% compared to the previous year[26]. - The company reported a total revenue of 2,000.00 million for the year, with a growth rate of 52.88% compared to the previous year[85]. - The company reported a revenue of 1.2 billion in 2021, representing a year-over-year growth of 15%[180]. - The company provided a revenue guidance of 1.8 billion RMB for the next fiscal year, which reflects an expected growth of 20%[187]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 3 per 10 shares, totaling an estimated cash dividend of RMB 24 million, which represents 39.18% of the net profit attributable to shareholders for 2021[7]. - The profit distribution plan is subject to approval at the company's annual general meeting, highlighting the need for shareholder consent before implementation[8]. - The company confirmed the proposal for the distribution of profits for the year 2020 during the annual shareholder meeting[171]. Research and Development - The company focused on expanding its CDMO services and enhancing overseas business development during the reporting period[39]. - The company has developed core technologies in peptide drug CDMO services, including "single sulfur ring peptide large-scale production" and "long-chain peptide coupling technology" to enhance its market competitiveness in innovative drugs[40]. - The company is committed to ongoing research and development of new technologies and products to address unmet medical needs in various therapeutic areas[54]. - The company has established a robust pipeline of products in various stages of development, indicating strong future growth potential in the pharmaceutical market[54]. - The total R&D investment for the year was approximately ¥18.33 million, a decrease of 18.49% compared to the previous year[80]. - R&D investment accounted for 4.74% of total revenue, with a capitalization ratio of 25%[145]. Market Expansion and Strategy - The company is expanding its market presence, targeting an increase in market share by 10% in the Asia-Pacific region over the next two years[18]. - The company is exploring new strategies for market expansion, including potential mergers and acquisitions to enhance its product offerings and market reach[54]. - Market expansion plans include entering three new international markets by the end of 2022[182]. - The company aims to strengthen its product development and technology platform, focusing on key areas such as oncology, diabetes, obstetrics, digestive system, and immune system diseases[157]. Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties, indicating a stable governance structure[11]. - The company has not violated decision-making procedures for external guarantees, reinforcing its compliance with regulations[11]. - The company maintained compliance with legal and regulatory requirements in all shareholder meetings[172]. - The company has not engaged in any related party transactions during the reporting period[174]. Risks and Challenges - The company has outlined various risks in its operations and has provided measures to address these risks, emphasizing the importance of investor awareness[5]. - The report includes a forward-looking statement risk declaration, cautioning investors about the uncertainties in future plans and strategies[10]. - The company faces risks related to research and development failures, which could lead to loss of competitive advantage if products do not meet regulatory approval[98]. - The company is exposed to financial risks, including potential issues with accounts receivable collection and foreign exchange fluctuations due to international operations[100]. Operational Efficiency - The gross margin improved to 60%, up from 55% in the previous year, reflecting better cost management and pricing strategies[18]. - The company has successfully reduced operational costs by 15% through efficiency improvements in the supply chain[187]. - The company reported a significant increase in technical service costs, which rose by 22.65% year-on-year to 1.97 million RMB[113]. Shareholder Engagement - The company held a total of 3 shareholder meetings during the reporting period, including 1 annual meeting and 2 extraordinary meetings[172]. - The board of directors and senior management did not experience any changes in shareholding during the reporting period, with all key personnel maintaining their shareholdings[174]. - The total pre-tax remuneration for the chairman and general manager, Wen Yongjun, was 640,800 RMB[174].